James P. Agalloco - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

James P. Agalloco


James P. Agalloco Pharmtech editorial advisory board (EAB) member

James P. Agalloco
President,
Agalloco & Associates

Agalloco is a past president of the Parenteral Drug Association (PDA) and served as an officer or director of PDA from 1982 to 1993. He has authored or co-authored more than 90 papers and lectured extensively on sterilization, aseptic processing, and validation at various PDA, PMA, the International Society for Pharmaceutical Engineering (ISPE), and Pharmaceutical Technology meetings, domestically as well as internationally. He is a member of USP’s Microbiology and Sterility Assurance Expert Committee for 2005–2010. Agalloco is a member of the editorial advisory boards of Pharmaceutical Technology and Pharmaceutical Manufacturing, and serves on the scientific advisory boards of Laureate, MEDInstill, MODA, and IPS.

He is a frequent author and lecturer on the subject of sterilization, aseptic processing, and process validation.

James Agalloco is president of Agalloco & Associates, which provides a range of technical services to the pharmaceutical and biotechnology industry. Since the formation of the company in 1991, Agalloco has assisted more than 100 healthcare firms in a wide range of validation, automation and compliance areas. During his more than 35 years of industry experience, he has worked in organic synthesis, pharmaceutical formulation, pharmaceutical production, project and process engineering, validation and process automation during his career at Merck, Pfizer, Squibb and Bristol-Myers Squibb.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here